CLL Managed Care
Value-Based Clinical Decision-Making for Chronic Lymphocytic Leukemia Managed in the Community Setting
Speakers: John Allan, Associate Professor of Clinical MedicineDr. Gary Owens, President
Duration: 60 minutes
Presented on: February 21, 2024
Associate Professor of Clinical MedicineJohn N. Allan, MD is an associate professor of clinical medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. Seeking an internal medicine residency program with particular strength in oncology, Dr. Allan moved to New York in 2009 to train at New York-Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his hematology and medical oncology fellowship. Dr. Allan treats all lymphoid malignancies and has a particular interest in improving therapies for patients with chronic lymphotic leukemia (CLL) and Richter’s syndrome, which is the focus of his research.
Dr. Gary Owens
Dr. Gary Owens
PresidentGary Owens, MD has 35 years of experience in healthcare management. He was actively involved in the managed care movement of the 1990s, which evolved to the current era of health care coverage and payment reform. Dr. Owens served as the Vice President of Medical Management and Policy at Independence Blue Cross for 22 years with responsibilities for medical and pharmacy management, technology evaluation, and medical policy. Forming his own consulting practice in 2007, Dr. Owens provides strategic and tactical consulting services to a wide range of clients, including pharmaceutical manufacturers, device manufacturers, and other developers of new technology.
Value-based Clinical Decision-making for Chronic Lymphocytic Leukemia Managed in the Community SettingJointly provided by American Association of Managed Care Nurses (AAMCN), National Association of Managed Care Physicians (NAMCP) and PlatformQ Health Education, LLC.
ACKNOWLEDGEMENTThis activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
DATE OF RELEASE/EXPIRATIONThis activity was released on February 21, 2024 and is valid until February 21, 2025. Requests for credit must be made no later than February 21, 2025.
TARGET AUDIENCEThe educational design of this activity addresses the needs of managed care medical directors, hematologist-oncologists, and other clinicians involved in the management of patients with Chronic Lymphocytic Leukemia (CLL).
STATEMENT OF NEED/PROGRAM OVERVIEWIn the past decade, the emergence of targeted therapy with Bruton tyrosine kinase inhibitors (BTKIs) has changed the treatment landscape for chronic lymphocytic leukemia (CLL). While these advances have allowed clinicians to treat a wider array of patients, especially those for whom chemoimmunotherapy is not optimal, a need remains for clinicians to stay up to date with the latest guidelines and approvals of newer BTKIs for various CLL indications. Join a panel featuring an expert in CLL and a managed-care medical director to discuss newer BTKIs, how to select the most appropriate therapy for various patient profiles, how to monitor patients, and how to manage treatment-related adverse events. Panelists will discuss patient-centered treatment strategies that include identifying and selecting those patients who are most likely to benefit from BTKIs, as well as the significance of defining high-risk patients.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Discuss the advantages of BTKIs over CIT for treatment of CLL and review guideline-based strategies for optimizing treatment
- Evaluate recent efficacy and safety data from clinical trials on second-generation BTKIs and determine their potential to provide targeted and safer treatment
- Outline CLL treatment plans based on BTKIs and considering each patient’s disease biology, genetic mutations, risk stratification, treatment response, and adverse events
ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American Association of Managed Care Nurses (AAMCN), National Association of Managed Care Physicians (NAMCP), and PlatformQ Health Education, LLC. NAMCP is accredited with commendation by the ACCME to provide continuing medical education to physicians.
PHYSICIAN CONTINUING EDUCATIONNAMCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATIONThe American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). Nurses who complete this activity will receive up to 1 contact hour in nursing continuing professional development.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 60 minutes to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™ or NCPD contact hours, participants must receive a score of 75% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
FACULTY AND DISCLOSURE OF CONFLICTS OF INTERESTNAMCP requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to NAMCP policy. NAMCP is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Faculty Conflicts of Interest John N. Allan, MD Associate Professor of Clinical Medicine Weill Cornell Medicine Consulting Fee/Advisory Board: AbbVie, Adaptive, ADC Therapeutics, BeiGene, Epizyme, Genentech, Janssen, Lava, Lilly, Pharmacyclics Grant/Research Support: BeiGene, Celgene, Genentech Speakers Bureau/Honoraria: AbbVie, BeiGene, Janssen, Pharmacyclics Gary M. Owens, MD President, Gary Owens Associates Consultant: ICON, Magnolia Innovation, Payer Sciences Consulting Fee/Advisory Board: Baxter, BD, CVRx, OcuTerra, Octave Biosciences, Regeneron, Sanofi Employee/Owner: Gary Owens Associates, Inc.
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Support:For additional information about the accreditation of this activity, please contact Jeremy Williams at firstname.lastname@example.org.
Technical Support:For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.